AE	adverse events
BRAF/MEKi	BRAF/MEK inhibitors
BRAF ± MEKi	BRAF with/or without MEK inhibitors
BSC	best-supportive care
CI	confidence interval
CPI	immune-checkpoint inhibitors
CR	complete response
CTLA-4	cytotoxic-T-lymphocyte antigen 4
DCR	disease-control rate
HR	hazard ratio
ICB	immune-checkpoint blockade
LDH	lactate dehydrogenase
MBM	melanoma brain metastases
ORR	overall response rate
OS	overall survival
PD	progressive disease
PD-1	programmed death protein 1
PFS	progression-free survival
PR	partial response
RCT	randomized controlled trial
SD	stable disease
Tx	treatments
TME	tumor microenvironment
TT	BRAF/MEK-directed targeted therapy
TTNT	time to next treatment
1L	front-line
2L	second-line